recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Von Willebrand Disease

Conditions

Von Willebrand Disease

Trial Timeline

Jul 1, 2004 → Dec 1, 2007

NCT ID

NCT00151125

About recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11

recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11 is a phase 2 stage product being developed by Pfizer for Von Willebrand Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00151125. Target conditions include Von Willebrand Disease.

What happened to similar drugs?

4 of 7 similar drugs in Von Willebrand Disease were approved

Approved (4) Terminated (0) Active (3)

✅Blood coagulation Factor VIII and vWF, humanCSLApproved

✅VoncentoCSLApproved

✅Alphanate SD/HTGrifolsApproved

✅plasma-derived FVIII/VWF concentrateGrifolsApproved

🔄Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing AgentsRochePhase 3

🔄BiostateCSLPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00151125	Phase 2	Completed	Jul 1, 2004	Dec 1, 2007	Von Willebrand Disease

Competing Products

14 competing products in Von Willebrand Disease

See all competitors

Product	Company	Stage	Hype Score
Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate	Roche	Pre-clinical	33
Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents	Roche	Phase 3	47
Neumega (Oprelvekin, Interleukin 11, IL-11)	Pfizer	Phase 2	27
Oprelvekin, Interleukin 11, IL-11	Pfizer	Phase 2	35
efanesoctocog alfa (BIVV001)	Sanofi	Phase 1	29
Biostate	CSL	Phase 3	40
Voncento®	CSL	Pre-clinical	26
Blood coagulation Factor VIII and vWF, human	CSL	Approved	43
Biostate® + Biostate®	CSL	Phase 2/3	38
VWF/FVIII products	CSL	Pre-clinical	26
Biostate	CSL	Phase 3	40
Voncento	CSL	Approved	43
Alphanate SD/HT	Grifols	Approved	44
plasma-derived FVIII/VWF concentrate	Grifols	Approved	47